3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
5
Terminated
1
Temporarily not available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
Thoracic
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Sarcoma, Ewing
1
Sarcoma
1
Rare Diseases
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Neoplasms
1
Interventions
Cyclophosphamide
26
Temozolomide
23
Doxorubicin
22
Radiotherapy
21
Filgrastim
19
Ifosfamide
15
pazopanib
14
Gemcitabine
14
Etoposide
13
Bevacizumab
13
Irinotecan
12
Cisplatin
12
Magnetic Resonance Spectroscopy
11
Imatinib Mesylate
11
Granulocyte Colony-Stimulating Factor
11
Carboplatin
11
Radiation
9
Methotrexate
9
pembrolizumab
8
fludarabine phosphate
8
Rituximab
8
Paclitaxel
8
Docetaxel
8
Cyclosporine
8
Busulfan
8
Antilymphocyte Serum
8
fludarabine
7
Vincristine
7
Radiotherapy, Intensity-Modulated
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
FANG vaccine
×
Sarcoma
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts